Tuesday, September 25, 2018


PRQR ProQR Therapeutics N.V. gains 153% Sep 25, 2018

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. The company's clinical stage candidates include QR-010, a RNA-based oligonucleotide that is in Phase Ib clinical trial for the treatment of cystic fibrosis. It also develops QR-110, which is in pre-clinical development stage for the treatment of Leber's congenital amaurosis. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive